The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
5-[(2,6-Difluoro-3,5-dimethoxyphenyl)methoxy]-N-{1-[2-(piperazin-1-yl)ethyl]-1H-pyrazol-4-yl}pyrimidin-2-amine trihydrochloride ID: ALA5201061
PubChem CID: 168291722
Max Phase: Preclinical
Molecular Formula: C22H30Cl3F2N7O3
Molecular Weight: 475.50
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc(OC)c(F)c(COc2cnc(Nc3cnn(CCN4CCNCC4)c3)nc2)c1F.Cl.Cl.Cl
Standard InChI: InChI=1S/C22H27F2N7O3.3ClH/c1-32-18-9-19(33-2)21(24)17(20(18)23)14-34-16-11-26-22(27-12-16)29-15-10-28-31(13-15)8-7-30-5-3-25-4-6-30;;;/h9-13,25H,3-8,14H2,1-2H3,(H,26,27,29);3*1H
Standard InChI Key: NCPIYNGRJGPLEP-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 37 0 0 0 0 0 0 0 0999 V2000
2.4508 -2.8432 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
-1.7945 -0.8249 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0799 -0.4126 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.3680 -0.8245 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.3680 -1.6496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0780 -2.0615 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.7945 -1.6534 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.3466 -2.0623 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.0612 -1.6496 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.5091 -0.4124 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.2237 -0.8249 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9384 -0.4124 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6532 -0.8247 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3653 -0.4127 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.3653 0.4126 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6550 0.8245 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.9384 0.4163 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.2237 0.8289 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-4.6550 1.6496 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-5.3696 2.0623 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.0799 -0.8253 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-6.0799 -1.6505 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.6532 -1.6499 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1.1474 -0.8295 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.9542 -0.6579 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.3666 -1.3722 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.8146 -1.9852 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.1918 -1.3722 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6044 -0.6576 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.4296 -0.6576 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.8422 0.0569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.6673 0.0569 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.0799 -0.6576 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.6673 -1.3722 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.8422 -1.3722 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.0089 -2.8432 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
0.6428 -2.8432 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
3 2 2 0
4 3 1 0
5 4 2 0
6 5 1 0
7 6 2 0
2 7 1 0
5 8 1 0
8 9 1 0
2 10 1 0
10 11 1 0
11 12 1 0
13 12 2 0
14 13 1 0
15 14 2 0
16 15 1 0
17 16 2 0
12 17 1 0
17 18 1 0
16 19 1 0
19 20 1 0
14 21 1 0
21 22 1 0
13 23 1 0
24 9 1 0
24 25 2 0
25 26 1 0
26 27 1 0
27 9 2 0
26 28 1 0
28 29 1 0
29 30 1 0
31 30 1 0
32 31 1 0
33 32 1 0
34 33 1 0
35 34 1 0
30 35 1 0
M END Associated Targets(Human) Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 475.50Molecular Weight (Monoisotopic): 475.2143AlogP: 2.20#Rotatable Bonds: 10Polar Surface Area: 98.59Molecular Species: BASEHBA: 10HBD: 2#RO5 Violations: ┄HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): ┄CX Acidic pKa: 11.87CX Basic pKa: 9.21CX LogP: 1.62CX LogD: -0.20Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.46Np Likeness Score: -1.41
References 1. Kuriwaki I, Kameda M, Iikubo K, Hisamichi H, Kawamoto Y, Kikuchi S, Moritomo H, Terasaka T, Iwai Y, Noda A, Tomiyama H, Kikuchi A, Hirano M.. (2022) Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity., 59 [PMID:35219181 ] [10.1016/j.bmc.2022.116657 ]